Story thread · 2 reports / 1 sources

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

seekingalpha.com · 2hShare

First report: Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning — seekingalpha.com, 1d